National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations... Show more
On September 04, 2025, the Stochastic Oscillator for NRC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 62 instances where the indicator left the oversold zone. In of the 62 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on September 05, 2025. You may want to consider a long position or call options on NRC as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
NRC moved above its 50-day moving average on September 05, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for NRC crossed bullishly above the 50-day moving average on September 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRC advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for NRC moved out of overbought territory on August 20, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for NRC turned negative on August 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for NRC entered a downward trend on August 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.667) is normal, around the industry mean (21.087). P/E Ratio (20.000) is within average values for comparable stocks, (81.565). NRC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.758). Dividend Yield (0.031) settles around the average of (0.062) among similar stocks. P/S Ratio (2.545) is also within normal values, averaging (104.827).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a provider of market research services for the healthcare industry
Industry ServicestotheHealthIndustry
A.I.dvisor indicates that over the last year, NRC has been loosely correlated with UPBD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NRC jumps, then UPBD could also see price increases.
Ticker / NAME | Correlation To NRC | 1D Price Change % | ||
---|---|---|---|---|
NRC | 100% | +2.94% | ||
UPBD - NRC | 46% Loosely correlated | +0.43% | ||
DOX - NRC | 42% Loosely correlated | +1.65% | ||
DJCO - NRC | 41% Loosely correlated | +0.12% | ||
QLYS - NRC | 41% Loosely correlated | +0.49% | ||
EEFT - NRC | 40% Loosely correlated | +0.32% | ||
More |
Ticker / NAME | Correlation To NRC | 1D Price Change % |
---|---|---|
NRC | 100% | +2.94% |
Health Services category (439 stocks) | 32% Poorly correlated | -0.08% |
Services to the Health Industry category (96 stocks) | 16% Poorly correlated | -1.85% |